- Conditions
- Kidney Failure, Chronic
- Interventions
- Repetitive arm exercise
- Other
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 1,094
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cardiac Arrhythmia, Blood Pressure
- Interventions
- Energy Drink Ingredients and Exercise
- Dietary Supplement
- Lead sponsor
- Duquesne University
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL
- Interventions
- Rituximab, Copanlisib, Bone Marrow Aspiration/Biopsy, CT Scans, 18F-FDG-PET/CT Scan15, Electrocardigram
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
- Interventions
- Carboplatin, Cisplatin, Computed Tomography, Durvalumab, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Methoxyamine, Pemetrexed, Radiation Therapy
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 34
- States / cities
- Buena Park, California • Duarte, California • Irvine, California + 27 more
- Conditions
- Contraception
- Interventions
- Polyurethane (PU) male condom-Test condom 1- PU 57 mm, Polyurethane (PU) male condom-Test condom 2- PU 63 mm, Natural Rubber Latex (NRL) male condom- Control condom
- Device
- Lead sponsor
- Reckitt Benckiser Healthcare (UK) Limited
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 598 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Berkeley, California • Los Angeles, California • Seattle, Washington
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Interventions
- Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography, Hormone Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
- Drug · Procedure · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 348
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 259 more
- Conditions
- Human Papillomavirus Infection
- Interventions
- Biomarker Analysis, Biospecimen Collection, Ultrasonography
- Other · Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 50 Years to 64 Years · Male only
- Enrollment
- 1,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy
- Interventions
- IMBRUVICA (Treatment A), Ibrutinib (Treatment B)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Plantar Fascitis
- Interventions
- Instrumental-assisted soft tissue mobilization (IASTM), High-Load Strength Training, Plantar Flexor and Gastrocnemius Stretching
- Other
- Lead sponsor
- Texas Tech University Health Sciences Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Lubbock, Texas
- Conditions
- Hearing Loss
- Interventions
- Mobile Research App (MRA), SOC/validated delivery of the speech perception test material
- Device · Other
- Lead sponsor
- Cochlear
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Lone Tree, Colorado
- Conditions
- Cutaneous Leishmaniasis
- Interventions
- Leishmania tropica Skin Test Antigen (LtSTA), Leishmania tropica Skin Test Antigen Placebo (Placebo)
- Biological
- Lead sponsor
- Nielsen BioSciences, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Erectile Dysfunction
- Interventions
- Nitric Oxide, Tadalafil, Placebo
- Dietary Supplement · Drug · Other
- Lead sponsor
- RHA Investments Ltd
- Industry
- Eligibility
- 40 Years to 65 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Body Composition, Circumference Measurements, Tissue Thickness Measurements
- Interventions
- Body Measurements, Body Composition and Circumference measurements, Whole Body DXA scan, Bioelectrical Impedance Analysis (BIA), BodPod, Circumferences, Ultrasound
- Other
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 5 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- PARKINSON DISEASE (Disorder)
- Interventions
- aDBS-Extended (Medtronic Percept™), aDBS-Standard (Medtronic Percept™), Continuous DBS (cDBS) - Active Control (Medtronic Percept™)
- Device
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- Infertility of Uterine Origin
- Interventions
- Endometrial biopsy and endometrial fluid collection
- Procedure
- Lead sponsor
- Igenomix
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 452 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Norwalk, Connecticut • Margate, Florida • Chesterfield, Missouri + 1 more
- Conditions
- Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
- Interventions
- Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography
- Drug · Biological · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 42
- States / cities
- Buena Park, California • Los Angeles, California • Newport Beach, California + 28 more
- Conditions
- Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma
- Interventions
- vincristine sulfate, irinotecan hydrochloride, cyclophosphamide, doxorubicin hydrochloride, ifosfamide, etoposide, tirapazamine, filgrastim, sargramostim, pharmacological study, pharmacogenomic studies, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 20 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Amputation
- Interventions
- Robotic Knee/Ankle Prosthesis
- Device
- Lead sponsor
- Georgia Institute of Technology
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Echocardiography Test, Electrocardiography, Lumbar Puncture, Mesna, Methotrexate, Multigated Acquisition Scan, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more
- Conditions
- Chemotherapy
- Interventions
- Hypothetical scenarios and related decisions
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Respiratory Failure, Intracranial Hypertension
- Interventions
- Esophageal Balloon catheter
- Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Sarcomatoid Urothelial Carcinoma, Kidney Medullary Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Penile Carcinoma, Penile Squamous Cell Carcinoma, Renal Cell Carcinoma, Renal Pelvis Urothelial Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 8
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 3 more
- Conditions
- Hypersensitivity
- Interventions
- Butenafine HCl 1% (BAY1896425), Positive Control-Sodium lauryl sulfate (SLS), Negative Control
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Fairfield, New Jersey
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, pH Low Insertion Peptide-exatecan Conjugate CBX-12
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland